GSK, the pharmaceutical group, is considering cutting around 1,200 jobs in Belgium
Last July, the GSK group, which is listed on the London Stock Exchange, announced that its net profit had fallen by more than two-thirds in the second quarter, a result weighed down by the suspension of the development of a drug for chronic cough
The British pharmaceutical group GSK has announced that it is considering cutting 1,200 jobs in Belgium as part of a cost-cutting plan to adapt to the fall in global demand for vaccines.
Its subsidiary, GSK Belgium, which employs over 8,000 people, is one of the largest employers in Wallonia, with three sites in the region. The restructuring, announced today, therefore affects around 15 per cent of the workforce.
“The aim is to align the organisation and industrial capacity with the structural evolution of global demand for certain vaccines,” the subsidiary stated in a press release. In terms of research and development (R&D), the group aims to “focus resources on priority projects”, it was emphasised.
Consequently, the restructuring plan “could affect up to 1,217 employees across the various Belgian sites. Production workers will not be affected by this reorganisation plan”.
Last July, the GSK group, which is listed on the London Stock Exchange, announced that its net profit had fallen by more than two-thirds in the second quarter, a result weighed down by the suspension of the development of a drug for chronic cough. Management also announced the launch of “a three-year cost-cutting programme”.
